Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Commonwealth Healthcare Corporation

Status: Completed

Conditions: Oral Squamous Cell Carcinoma (OSCC)

Treatments: Drug: pembrolizumab and cetuximab

Study type: Observational

Funder types: Other

Identifiers

NCT07015333

5-2025 Oral Cancer

Details and patient eligibility

About

Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.

Enrollment: 31 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced betel nut-induced oral cancer

Exclusion criteria

• None